Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients
To the Editor: Vismodegib is a hedgehog pathway inhibitor approved for treating locally advanced and metastatic basal cell carcinoma. Cramps (muscular spasms) are among vismodegib's major adverse effects (40%-80% of patients). 1, 2 In the pivotal study of Sekulic et al, 72 .1% of treatment discontinuation occured within the first year of follow-up. 2 A recent study shows that stretching muscles before going to sleep reduces both the frequency and severity of nighttime cramps. 3 Our objective was to characterize cramps and discuss an appropriate treatment.
We assessed the occurrence and evolution of cramps in all patients treated with vismodegib at Lille University Hospital (Supplementary Appendix; available at http://www.jaad.org), in a prospective study conducted during September 2014-November 2015. Patients completed a questionnaire that was developed in collaboration with a specialist in neuromuscular diseases to determine the characteristics of patient muscle spasms. We evaluated the benefits of hydration and muscle stretching performed by physiotherapists or by patients themselves following guidelines from a recent study. 3 Thirty patients were included in this study; 72% experienced muscle spasms, with 14% categorized as grade III according to Common Terminology Criteria for Adverse Events. The median duration (range) of treatment with vismodegib was 6.2 (0.59-10.97) months. Nineteen patients (65.5%) discontinued treatment during the year following the initiation. Seventeen of these 19 (89%) presented with muscle spasms; 12 patients stopped treatment because of adverse events and 6 because of cramps. We found a significant difference in vismodegib discontinuation ratios between patients with and without muscles spasms (P ¼ .0311). Patients usually stopped treatment after 6 months because of good response or the occurrence of toxicity. Sekulic et al observed a lower discontinuation rate related to adverse events (17%), but 23% had stopped treatment following their own judgment. 2 Side effects could have been one of the reasons. In our study, muscle spasms appeared, on average, 2 months after treatment initiation. Patients with higher-grade muscle spasms had earlier and rapidly worsening symptoms (Table I ; Supplementary Appendix). 1, 2 Among the 19 patients suffering from muscle spasms, 13 agreed to complete the questionnaire, and results were heterogeneous. Muscle spasms affected lower (92%) and upper (53.8%) limbs, occurred at night (84.6%), at rest (75%), and affected daily activities. Symptoms were described as painful peaks (84.6%). Thirty-eight percent suffered on a daily basis and 23.1% several times a week. (Table II) . 4, 5 Eight patients with muscle spasms persisting for [1 month were prescribed stretching (Supplemental Fig 1, A-C; available at http:// www.jaad.org) and hydration. Six of these patients (75%) improved; 5 patients had a grade decrease from II to I, and 1 patient expressed general improvement. Vismodegib was continued. No treatment (magnesium, baclofen, gabapentine, quinine benzoate) had a significant effect on muscle spasms. Patients in our cohort were mainly [60 years of age and on multiple medications. Managing cramps with stretching exercises without additional medications can help prevent other drug-induced toxicity and interactions in elderly patients. To the Editor: The multidisciplinary tumor board (MTB) is a meeting of various medical specialties to discuss the management of patients with cancer. In lung, esophageal, and head and neck cancers, tumor boards increase adherence to national treatment guidelines, decrease treatment delays, are educational, and instill the importance of multidisciplinary care early in training. [1] [2] [3] [4] However, little is known about the MTB for cutaneous neoplasms. This study assesses the structure, goals, and participation patterns of the MTB in a nationwide sample of academic dermatology centers.
Over 6 weeks, 3 requests to complete an online survey (Appendix 1 available at http://www.jaad. org) were emailed to all 119 dermatology residency programs accredited by the Accreditation Counsel of Graduate Medical Education as of January 5, 2016. 5 The results are presented in Table I . Fifty of 119 Patients with Gorlin syndrome were allowed to participate. Approval and waiver of informed consent in agreement with French regulations concerning such studies was obtained.
Treatment and follow-up
Vismodegib was prescribed at a standard dosage regimen of 150 mg daily. Follow-up was performed by a dermatologist each month. Side effects were graded using the Common Terminology Criteria for Adverse Events v4.0: grade I was mild pain, grade II was pain interfering with instrumental activities of daily life, and grade III was pain interfering with basic activities of daily life. Standard blood tests revealing magnesium and creatine kinase (CK) levels were performed at each visit. The efficiency of muscle spasm treatments (magnesium, quinine) and the efficiency of physiotherapy were measured by recording changes in cramp Common Terminology Criteria for Adverse Events grades and patients' general impressions.
Other results
No relationship between muscle spasms and high CK levels was identified. No variation in magnesium levels was observed in our patients. Four patients who were examined by a neurologist did not present with signs of neuropathy. We performed electromyograms on 2 patients with major muscle spasms and 1 patient with grade I muscle spasms. No sign of neuropathy was identified.
The literature
Similar side effects have been reported with sonidegib-another hedgehog pathway inhibitor-in 51.9% of patients treated with a 200-mg dose and in 69.3% of patients treated with a 800-mg dose, suggesting a class effect. Similarly to vismodegib cases, muscle spasms were the main reason for frequent discontinuation of sonidegib treatment. S1 In other studies, magnesium therapy did not appear to be effective in the treatment of nighttime leg cramps either.
S2
Quinine (200-500 mg daily) does not seem to significantly reduce muscle spasms, and some countries have restricted its use because of the serious adverse effects it can cause. 
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Hamstring and calf stretch (sitting position)
Starting position : Sit on the ground with both legs straight out. Grab both feet with hands. Stretching exercise: Lean forward while keeping back straight. Stretch should be felt in both calves and hamstrings.
Hold for 10 seconds.
